CONTACT US TODAYto schedule a lecture at your institution!

REDUCING THE BURDEN OF

Educational Lectures for Physicians, Pharmacists, and Nurses

This activity is supported by an educational grant from Optimer

Jointly sponsored/Co-provided by Robert Michael Educational Institute LLCand Postgraduate Institute for Medicine

Food and beverage provided upon request

2 Convenient Options to provide CME/CE Credit for this Educational Activity:

Option 1We provide free CME credit forphysicians and free CE credit fornurses and pharmacists

Option 2Your institution provides CME and/or CE credit

CONTACT US TODAYto schedule a lecture at your institution!

www.RMEI.com/CDILectures

CONTACT US TODAY

to schedule a lecture at your institution!

www.RMEI.com

/CDILectures

FROM INITIAL TREATMENT TO RECURRENCE PREVENTION

Clostridium difficileInfection:

RED

UCING THE BURDEN

OF

FROM IN

ITIAL TREATMEN

T

TO RECURREN

CE PREV

ENTION

Clo

stri

dium

dif

ficile

Infection:

PHYSICIAN CONTINUING EDUCATIONACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the Essential Areas andpolicies of the Accreditation Council for Continuing Medical Education through the joint spon-sorship of the Postgraduate Institute for Medicine and Robert Michael Educational Institute LLC.The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuingmedical education for physicians.

CREDIT DESIGNATIONThe Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATIONACCREDITATION STATEMENT

The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATIONThe Postgraduate Institute for Medicine designates this continuing education activity for 1.0contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (UniversalActivity Number—809-9999-11-096-L01-P)

ACPE RELEASE DATE: TBDACTIVITY TYPE: Knowledge

PHARMACY EDUCATIONAL OBJECTIVEAfter completing this activity, the participant should be able to:• Provide accurate and appropriate counsel as part of the treatment team

NURSING CONTINUING EDUCATIONCREDIT DESIGNATIONThis educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

ACCREDITATION STATEMENTThe Postgraduate Institute for Medicine is accredited as a provider of continuingnursing education by the American Nurses Credentialing Center’s Commission onAccreditation.

CALIFORNIA BOARD OF REGISTERED NURSINGThe Postgraduate Institute for Medicine is approved by the California Board of RegisteredNursing, Provider Number 13485 for 1.2 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation formand will be mailed to you within 4 weeks.

NURSING EDUCATIONAL OBJECTIVEAfter completing this activity, the participant should be able to:• Provide appropriate care and counsel for patients and their families

FEE INFORMATIONThere is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTERESTThe Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors,planners, managers and other individuals who are in a position to control the content of CMEactivities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM forfair balance, scientific objectivity of studies utilized in this activity, and patient care recom-mendations. PIM is committed to providing its learners with high quality CME activities andrelated materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

FACULTY Stuart Johnson, MD, DTM&H (Chair)Professor of Medicine Loyola University Medical Center Stritch School of Medicine Maywood, Illinois Staff Physician Hines VA Hospital Hines, Illinois

Saima Aslam, MD, MS Assistant ProfessorDivision of Infectious DiseasesUniversity of CaliforniaSan Diego, California

John G. Bartlett, MD, FACP, FIDSAProfessor of Medicine, Department of MedicineThe Johns Hopkins University School of MedicineBaltimore, Maryland

David G. Binion, MDVisiting Professor of MedicineCo-Director, Inflammatory Bowel Disease CenterUniversity of Pittsburgh Medical CenterPittsburgh, Pennsylvania

John A. Bosso, PharmD, FCCP Professor and ChairClinical Pharmacy and Outcome SciencesSouth Carolina College of PharmacyProfessor, Division of Infectious DiseasesMedical University of South Carolina College of MedicineCharleston, South Carolina

Stephen M. Brecher, PhD Director of MicrobiologyVA Boston Healthcare SystemWest Roxbury, MassachusettsAssistant Professor of PathologyBoston University School of MedicineBoston, Massachusetts

David S. Burgess, PharmD, FCCP Clinical Professor and Division HeadPharmacotherapy Division and Center for Advancement of Research and Education in Infectious Diseases

College of PharmacyUniversity of Texas at AustinClinical Professor of MedicineDepartment of Medicine, Division of Infectious Diseases

Director, Pharmacotherapy Education and Research Center

University of Texas Health Science Center at San Antonio

San Antonio, Texas

Roy F. Chemaly, MD, MPH, FACP, FIDSA Associate Professor of MedicineDirector, Infection Control Section Director of Clinical VirologyDepartment of Infectious Diseases, Infection Control and Employee Health

University of Texas MD Anderson Cancer Center Houston, Texas

Lynn Chilton, DSN, RN, GNP-BC/FNP-BCProfessor, Coordinator of the Adult-Geron Nurse Practitioner Program

University of South Alabama College of Nursing Mobile, Alabama

Stuart H. Cohen, MD, FACP, FIDSAProfessor of MedicineDivision of Infectious DiseasesDirector of Hospital Epidemiology and Infection Control

University of California, Davis Medical CenterSacramento, California

Erik R. Dubberke, MD, MSPHAssistant Professor of MedicineInfectious Diseases Division, Department of Medicine

Washington University School of MedicineAssociate Hospital EpidemiologistBarnes-Jewish HospitalMedical Director, Infection ControlMissouri Baptist Medical CenterSt. Louis, Missouri

Douglas N. Fish, PharmD, FCCM, FCCP, BCPSProfessor and ChairDepartment of Clinical PharmacyUniversity of Colorado, DenverSchool of PharmacyAurora, Colorado

Frank K. Friedenberg, MD, MS (Epi)Professor of MedicineDepartment of GastroenterologyTemple University School of MedicinePhiladelphia, Pennsylvania

Dale N. Gerding, MD, FIDSAProfessor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IllinoisAssociate Chief of Staff for ResearchHines Veterans Affairs Hospital Hines, Illinois

Ciarán P. Kelly, MD Professor of Medicine Harvard Medical School Chief, Herrman L. Blumgart Internal Medicine Firm

Director, Gastroenterology Fellowship Training Director, Celiac Center Beth Israel Deaconess Medical Center Boston, Massachusetts

Ben M. Lomaestro, PharmDSenior Clinical Pharmacy Specialist in Infectious Diseases

Albany Medical Center Hospital Albany, New York

Linda M. Mundy, MD Adjunct Assistant ProfessorDepartment of Community HealthSaint Louis University School of Public HealthSt. Louis, MissouriHealthcare ConsultantLM Mundy, LLCPhiladelphia, Pennsylvania

Kathleen Mullane, DO, PharmDAssociate Professor of MedicineUniversity of ChicagoChicago, Illinois

Carlene A. Muto, MD, MS Medical DirectorDepartment of Hospital Epidemiology and Infection Control

University of Pittsburgh Medical Center Pittsburgh, Pennsylvania

David P. Nicolau, PharmD, FCCP, FIDSADirector, Center for Anti-Infective Research and Development

Hartford HospitalHartford, Connecticut

Jorge P. Parada, MD, MPH, FACP, FIDSA Professor of MedicineMedical Director, Infection Control ProgramDirector, MRSA ClinicResearch Associate, Infectious Diseases and Immunology Institute

Division of Infectious Diseases, Fahey CenterLoyola University Medical CenterStritch School of MedicineMaywood, IllinoisSenior Research AssociateCenter of Management of Complex Chronic Care

Hines VA HospitalHines, Illinois

Charalabos Pothoulakis, MD, DSci Director, Inflammatory Bowel Disease CenterDivision of Digestive Diseases, David GeffenSchool of Medicine

University of California, Los AngelesProfessor of MedicineEdythe and Eli Broad Chair in MedicineLos Angeles, California

Connie S. Price, MD Chief of Infectious DiseasesMedical Director of Infection Control and Prevention

Denver Health Medical CenterProfessor of MedicineDivision of Infectious DiseasesUniversity of ColoradoDenver, Colorado

Susan Whittier, PhD, ABMMAssociate DirectorClinical Microbiology ServiceNew York Presbyterian/Columbia University Medical Center

Assistant Professor of Clinical PathologyCollege of Physicians and SurgeonsNew York, New York

Marya D. Zilberberg, MD, MPHPresident and CEO EviMed Research Group, LLCGoshen, MassachusettsAdjunct Assistant ProfessorDepartment of Health Policy and ManagementSchool of Public Health and Health SciencesUniversity of MassachusettsAmherst, Massachusetts

REDUCING THE BURDEN OF

FROM INITIAL TREATMENT TO RECURRENCE PREVENTION

Clostridium difficile Infection:

2 Convenient Options to provide CME/CE Credit forthis Educational Activity:

Option 1 We provide free CME credit for physicians and free CE credit for nurses and pharmacists

Option 2 Your institution provides CME and/or CE credit

Contact us today to schedule a lecture at your institution!

Online:www.RMEI.com/CDILectures

Toll-free:877-547-5640

TARGET AUDIENCEThis activity is designed to meet the educational needs of physicians, pharmacists, andregistered nurses involved in the treatment of patients with Clostridium difficile infection(CDI).

STATEMENT OF NEEDIn recent years, significant changes have occurred in the epidemiology and treatment of Clostridium difficile infection (CDI).1 Increasing frequency of disease and hypervirulentC. difficile strains have resulted in more severe disease and therapeutic failures with traditional treatments.2 CDI rates have increased in patient populations previouslythought to be at low risk including children, pregnant women, and patients with inflam-matory bowel disease.3 CDI recurrence remains an important clinical problem for patients and healthcare providers. Importantly, innovative therapies are emerging for the treatment of CDI. As always, infection control measures remain paramount inlimiting the spread of disease. In order to improve patient outcomes in CDI, healthcareprofessionals must be aware of the changing epidemiology, risk factors for recurrence,emerging novel treatment strategies, and methods of prevention.1 Cohen SH, et al. Infect Control Hosp Epidemiol. 2010;31(5):431-455.2 Venuto C, et al. Pharmacotherapy. 2010;30(12):1266-1278.3 Ananthakrishnan AN. Nat Rev Gastroenterol Hepatol. 2010;8(1):17-26.

EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:

• Discuss the pathophysiology of Clostridium difficile infection (CDI) as it relates to clinical disease

• Analyze elements which contribute to the economic burden of CDI• Identify important risk factors for initial CDI and recurrence• Apply therapeutic strategies for improved patient outcomes• Implement methods to prevent CDI in high-risk patients

ACTIVITY AGENDAOverview ......................................................................................................................... 5 minutesPresentation ................................................................................................................... 45 minutesQ&A Session .................................................................................................................. 10 minutes

follow us on twitter twitter.com/RMEIMedEd

find us on facebook facebook.com/FreeCME

30-11-411-LS